Filing Flows › Bruker (BRKR) › Q2 2026 › vs Q1 2026
Bruker (BRKR) Q2 2026 vs Q1 2026 (quarter over quarter)
Bruker's revenue rose $15.1M (+2%) from $823M in Q1 2026 to $838M in Q2 2026. The biggest changes: Bsi Nano +$15.3M (+6%); Energy and Supercon Technologies +$7.6M (+12%); Bsi Calid −$6.0M (-2%).
Bruker, Q2 2026: revenue $838M (+5% year over year), operating margin -7.8%, net loss $50.9M, operating cash flow −$77.4M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Bsi Calid | $310M | $316M | −$6.0M | -2% |
| Bsi Nano | $261M | $246M | $15.3M | +6% |
| Bsi Biospin | $196M | $198M | −$1.8M | -0.9% |
| Energy and Supercon Technologies | $71.2M | $63.6M | $7.6M | +12% |
| Revenue | $838M | $823M | $15.1M | +2% |
| Other income, net | $28.6M | $8.0M | $20.6M | +258% |
| Net loss | $50.9M | −$15.7M | $66.6M | — |
| Costs & expenses | $918M | $831M | $86.6M | +10% |
| Operating costs | $904M | $813M | $90.6M | +11% |
| Income tax | $14.2M | $2.5M | $11.7M | +468% |
| Cost of revenue | $422M | $444M | −$21.1M | -5% |
| Research & development | $94.3M | $101M | −$7.0M | -7% |
| SG&A | $239M | $242M | −$3.2M | -1% |
| Other operating costs | $148M | $26.2M | $122M | +465% |
| Operating cash sources | $141M | −$6.9M | $148M | — |
| Depreciation & amortization | $58.0M | $58.3M | −$300K | -0.5% |
| Share-based compensation | $5.6M | $6.0M | −$400K | -7% |
| Cash used in operations | $77.4M | −$71.2M | $149M | — |
| Net loss absorbed | $50.9M | −$15.7M | $66.6M | — |
| Working capital & other | $90.1M | $8.8M | $81.3M | +924% |
Questions
How much did Bruker's revenue grow quarter over quarter in Q2 2026?
Bruker's revenue rose $15.1M (+2%) from $823M in Q1 2026 to $838M in Q2 2026.
What drove Bruker's revenue change in Q2 2026?
Bsi Nano +$15.3M (+6%); Energy and Supercon Technologies +$7.6M (+12%); Bsi Calid −$6.0M (-2%).